Enriched Heparin Anti COVID-19 Trial

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

November 30, 2021

Study Completion Date

December 31, 2021

Conditions
Covid19
Interventions
DRUG

Heparin sodium

Nebulized inhalation of 5 mL of a solution containing high molecular weight heparin - enriched heparin - 2.5mg/mL and 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)

DRUG

Placebo

Nebulized inhalation of 5 mL of 0.9% saline solution, every 4 hours for 7 days, except during the nighttime (5 doses/day)

Trial Locations (2)

18607030

School of Medicine at Botucatu- Paulista State University- UNESP, São Paulo, Brazil, Botucatu

18618970

Hospital das Clinicas de Boucatu, Botucatu

All Listed Sponsors
lead

UPECLIN HC FM Botucatu Unesp

OTHER